Pharma MT and Australian medical cannabis company MediPharm LABS have signed a new agreement, which will see MediPharm provide “premium, GMP certified, finished dose cannabis oil for patients”.

Under the deal, which will run for an initial term of two years, subject to further renewals, Pharma MT will work with MediPharm Labs to provide "full-spectrum cannabis concentrates” to be distributed to patients through pharmacies that will complete the final formulation and fill processes.

Celebrating the agreement on social media Adam Isaac Mille, Head of Strategic Accounts (Asia-Pacific) at MediPharm, said the agreement showed the company knocking “on Malta’s door”.

In the last three months, he explained, MediPharm has completed the export of cannabis-based derivative products to customers in Germany, Peru and Australia, and expects to begin exports to other countries later in the year, including Brazil, Malta, Denmark and New Zealand.

Pharma MT offers a range of services related to the distribution and marketing of Pharmaceuticals and other pharmacy-based and beauty products, in addition to those relating to licensing and regulatory hurdles involved in registering products for the European market.